Kash 120 Tablet SR is a combination medication containing Montelukast 10 mg, Fexofenadine 120 mg, and Acebrophylline 200 mg, formulated to provide comprehensive management of respiratory conditions characterized by allergic inflammation, bronchoconstriction, and mucus hypersecretion. Montelukast, a leukotriene receptor antagonist, effectively reduces airway inflammation and bronchospasm by blocking leukotriene D4 at the cysteinyl leukotriene receptor, thereby improving symptoms in asthma and allergic rhinitis. Fexofenadine, a second-generation antihistamine, selectively inhibits peripheral H1 receptors, alleviating allergic symptoms such as sneezing, nasal congestion, and urticaria without causing significant sedation. Acebrophylline, a bronchodilator with mucolytic and anti-inflammatory properties, facilitates airway clearance by relaxing bronchial smooth muscle and reducing mucus viscosity, enhancing respiratory function in obstructive airway diseases like chronic bronchitis and COPD. The sustained-release formulation ensures prolonged therapeutic action, improving patient compliance by reducing dosing frequency. Kash 120 Tablet SR is indicated for the symptomatic treatment of allergic asthma, chronic obstructive pulmonary disease with an allergic component, and other respiratory disorders requiring combined anti-inflammatory, antihistaminic, and bronchodilator therapy. It should be used under medical supervision, considering contraindications, potential drug interactions, and patient-specific factors to optimize efficacy and safety.